Futibatinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Futibatinib production plant. It encompasses all critical aspects necessary for Futibatinib production, including the cost of Futibatinib production, Futibatinib plant cost, Futibatinib production costs, and the overall Futibatinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Futibatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Futibatinib is an oncology drug used mainly for treating cancers driven by abnormal FGFR2 gene fusions or rearrangements. It is used as an oral cancer medication in the treatment of cholangiocarcinoma, which is a rare form of bile duct cancer, especially in patients with FGFR2 gene fusions or rearrangements. It works by blocking FGFR (fibroblast growth factor receptors), which play a role in the growth of cancer cells. It is primarily used in targeted cancer therapy for its effectiveness in cases where traditional chemotherapy shows limited results.

It is also being explored in clinical studies for other solid tumours that show FGFR alterations, including certain types of breast, gastric, and bladder cancers. In research settings, Futibatinib is used for its ability to act as an irreversible FGFR inhibitor, which helps scientists study signalling pathways involved in cancer progression.

The market for Futibatinib is primarily led by its application as a targeted cancer therapy for treating tumours with FGFR2 alterations, which fuels its demand in the oncology and pharmaceutical industries. Its application as a drug in managing advanced cholangiocarcinoma further promotes its demand in the medical and pharmaceutical industries. Its usage as a drug in combination with immunotherapies and other targeted treatments also promotes its demand in the medical sector.

Its involvement in clinical research for treating other FGFR-related tumours also drives its demand in the research and biomedical industries. Its involvement in ongoing clinical studies to explore its use in treating other solid tumours also drives its market growth. Improvements in synthesis routes, dependable supplier networks, responsible sourcing practices, and efficient global logistics also influence procurement trends and help shape the global market for Futibatinib. Additionally, industrial Futibatinib procurement depends on factors such as the cost and availability of specialised raw materials, adherence to strict production and regulatory standards, and compliance with environmental and safety rules.

Raw Material for Futibatinib Production

According to the Futibatinib production plant project report, the major raw materials for Futibatinib production include 2-Methanesulfonate, Aqueous Sodium Hydroxide, and 3-Chloropropionyl Chloride.

Production Process of Futibatinib

The extensive Futibatinib production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Futibatinib begins with dissolving 2-methanesulfonate in a mixture of water and acetonitrile, followed by the addition of aqueous sodium hydroxide. A solution of 3-chloropropionyl chloride in acetonitrile is then added slowly, and the mixture is stirred to allow the reaction to proceed. Once intermediate impurities are minimised, more sodium hydroxide is added, and the mixture is stirred further to ensure complete conversion. Then, water is gradually introduced to the reaction mixture to facilitate precipitation. After adjusting the temperature and stirring, the solid product is collected by filtration, washed with water, and dried under reduced pressure to obtain Futibatinib as the final product.

Futibatinib is a synthetic small-molecule anticancer compound that appears as a white to off-white solid with no distinct odour. The molecular formula of the compound is C22H22N6O3, and its molar mass is about 418.45 g/mol. It is sparingly soluble in water but more soluble in certain organic solvents, such as DMF, DMSO, and ethanol. It has a density of around 1.33 g/cm3 and a very high boiling point of around 734 degree Celsius. The compound is generally stored at -20 degree Celsius. It is used as an irreversible inhibitor of fibroblast growth factor receptors in the treatment of certain advanced cancers. Appropriate protective measures should be taken when handling the pure chemical because, like many active pharmaceutical ingredients, it can pose health risks if mishandled.